Watchlist Price Alert

Apimeds Pharmaceuticals U... (APUS)

NYSE: APUS · Real-Time Price · USD

1.72

0.09 (5.52%)

At close: Jun 23, 2025, 1:04 PM

Apimeds Pharmaceuticals US Inc Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-1.28M	-1.56M	-1.36M	-962.78K	-747.44K	-254.55K	-150.39K	-122.57K	-66.19K
Interest Income	2.82K	8.38K	10.49K	9.97K	7.81K	2.23K	n/a	n/a	n/a
Pretax Income	-1.39M	-1.65M	-1.42M	-1.01M	-777.69K	-285.32K	-175.3K	-139.23K	-74.59K
Net Income	-1.39M	-1.65M	-1.42M	-1.01M	-777.69K	-285.32K	-175.3K	-139.23K	-74.59K
Selling & General & Admin	1.28M	1.53M	1.34M	914.79K	648.89K	122.44K	15.29K	9.9K	4.07K
Research & Development	n/a	28.55K	25.55K	47.99K	98.54K	132.11K	135.11K	112.67K	62.12K
Other Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	1.28M	1.56M	1.36M	962.78K	747.44K	254.55K	150.39K	122.57K	66.19K
Interest Expense	117.72K	95.15K	70.6K	56.73K	38.07K	33K	24.91K	16.66K	8.41K
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	1.28M	1.56M	1.36M	962.78K	747.44K	254.55K	150.39K	122.57K	66.19K
Income Tax Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M	11.53M
Shares Outstanding (Diluted)	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M	12.69M
EPS (Basic)	-0.12	-0.14	-0.12	-0.09	-0.07	-0.02	-0.02	-0.01	-0.01
EPS (Diluted)	-0.11	-0.13	-0.11	-0.08	-0.06	-0.02	-0.01	-0.01	-0.01
EBITDA	-1.27M	-1.55M	-1.35M	-952.81K	-739.63K	-252.32K	-150.39K	-122.57K	-66.19K
EBIT	-1.27M	-1.55M	-1.35M	-952.81K	-739.63K	-252.32K	-150.39K	-122.57K	-66.19K
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a